Drug Type Small molecule drug |
Synonyms BI 685509, BI-685509, BI685509 |
Target |
Mechanism sGC stimulants(Soluble guanylate cyclase stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC34H38N4O5 |
InChIKeyKWNFFNFBUMFTHK-UHFFFAOYSA-N |
CAS Registry1579514-06-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Liver Cirrhosis | Phase 2 | AU | 27 Feb 2024 | |
Liver Cirrhosis | Phase 2 | AU | 27 Feb 2024 | |
Scleroderma, Systemic | Phase 2 | US | 14 Dec 2022 | |
Scleroderma, Systemic | Phase 2 | US | 14 Dec 2022 | |
Scleroderma, Systemic | Phase 2 | JP | 14 Dec 2022 | |
Scleroderma, Systemic | Phase 2 | JP | 14 Dec 2022 | |
Scleroderma, Systemic | Phase 2 | AR | 14 Dec 2022 | |
Scleroderma, Systemic | Phase 2 | AR | 14 Dec 2022 | |
Scleroderma, Systemic | Phase 2 | AU | 14 Dec 2022 | |
Scleroderma, Systemic | Phase 2 | AU | 14 Dec 2022 |
Phase 2 | 50 | BI-685509 30 mpk/day | lagsqtmppw(cfxntkuvhz) = jtgmzowwdw cwitmsrhtz (josvgieosv ) View more | Positive | 05 Nov 2022 | ||
BI-685509 100 mpk/day | lagsqtmppw(cfxntkuvhz) = epfmssfhlj cwitmsrhtz (josvgieosv ) View more |